MKMuhammed Kandemir

Muhammed Kandemir

*This is an algorithmically generated author record based on publicly available information.

Muhammed Kandemir has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Primary neuroendocrine tumor of the perihilar bile duct: A case report

    by Mustafa Salış, Muhammed Kandemir, Elif Gündoğdu, İlTer Özer, Bülent Ünal, Murat Ulaş

    Neuroendocrine tumors (NETs) arising from extrahepatic bile ducts are very rare. We present a patient with perihilar NET who was operated on with a preoperative diagnosis of Klatskin tumor. A 58-year-old female patient was admitted with abdominal pain and jaundice. Laboratory data showed elevated serum bilirubin levels and liver function tests. Computed tomography (CT) and magnetic resonance cholangiopancreatography (MRCP) findings were consistent with perihilar bile duct tumor. The patient was operated on with a diagnosis of Klatskin tumor. She underwent right hepatectomy, resection of the extrahepatic bile duct, portal lymphadenectomy and Roux-en-Y hepaticojejunostomy. The final pathologic examination of the resected specimen demonstrated a well differentiated neuroendocrine tumor (Grade 1). NETs originating from perihilar bile ducts are extremely rare, and preoperative definite diagnosis is very difficult. It should be kept in mind that NET may be one of the rare causes of perihilar bile duct obstruction.

  • Open Access

    The role of anakinra in the modulation of intestinal cell apoptosis and inflammatory response during ischemia/reperfusion

    by Muhammed Kandemi̇r, Necdet Fatih Yaşar, Mete Özkurt, Rumeysa Özyurt, Nuriye Ezgi Bektur Aykanat, Nilüfer Erkasap

    Even though interleukin-1 receptor antagonist, IL-1Ra, is used in certain inflammatory diseases, its effect on ischemia-reperfusion injury is a current research topic. We aimed to investigate the protective effects of anakinra, an IL-1Ra, on the I/R induced intestinal injury. The rat model of intestinal ischemia-reperfusion was induced. Rats were randomized into four groups: (group 1) control group, (group 2) I/R group, (group 3 and 4) treatment groups (50mg/kg and 100mg/kg, respectively). Gene expressions of Caspase-3, TNF-?, IL-1?, IL-6, and apoptotic cells in tissue samples were evaluated by PCR and TUNEL methods, respectively. Plasma levels of SOD, CAT, and MDA were studied by the ELISA method and tissue samples were examined histopathologically as well. Anakinra inhibited the expression of IL-1?, IL-6, and TNF-? and decreased the SOD, CAT, and MDA caused by ischemia-reperfusion injury in both treatment groups. Caspase-3 expression and TUNEL-positive cell number in treatment groups as well were less. Histopathologically, anakinra better preserved the villous structure of the small intestine at a dose of 100 mg/kg than 50 mg/kg. Anakinra decreased the intestinal damage caused by ischemia-reperfusion and a dose of 100mg/kg was found to be histopathologically more effective.